Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
RESEARCH TOOLSreports
Holding AU:NEU?
Track your performance easily
NEU Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$10.02 - AU$25.95
Previous CloseAU$13.38
Volume84.43K
Average Volume (3M)454.91K
Market Cap
AU$1.89B
Enterprise ValueAU$1.70B
Total Cash (Recent Filing)AU$40.18M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)14.5
Beta0.52
Next Earnings
Mar 04, 2025EPS Estimate
AU$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.92
Shares OutstandingN/A
10 Day Avg. Volume380,863
30 Day Avg. Volume454,909
Standard Deviation0.25
R-Squared0.22
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)123.60
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$26.50Price Target Upside79.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Neuren Pharmaceuticals Limited News
PremiumCompany Announcements
Neuren Pharmaceuticals Sees Surge in H1 Revenue
PremiumCompany Announcements
Neuren Pharmaceuticals Posts Sharp Profit Decline
PremiumCompany Announcements
Neuren Aims to Transform Neurodevelopmental Care
PremiumCompany Announcements
Neuren Pharmaceuticals Director Increases Stake
PremiumCompany Announcements
Neuren Pharmaceuticals Reports Phase 2 Trial MilestonePremiumCompany Announcements
Neuren’s Trial Suggests Breakthrough in Angelman Syndrome
PremiumCompany Announcements
Neuren Pharmaceuticals Awaits Key Clinical Trial ResultsPremiumCompany Announcements
Neuren Pharma’s Q2 Growth and Clinical AdvancesOptions Prices
Currently, No data available
---
Ownership Overview
35.87% Insiders
2.51% Mutual Funds
2.91% Other Institutional Investors
58.71% Public Companies and
Individual Investors
NEU FAQ
What was Neuren Pharmaceuticals Limited’s price range in the past 12 months?
Neuren Pharmaceuticals Limited lowest share price was AU$10.02 and its highest was AU$25.95 in the past 12 months.
What is Neuren Pharmaceuticals Limited’s market cap?
Currently, no data Available
When is Neuren Pharmaceuticals Limited’s upcoming earnings report date?
Neuren Pharmaceuticals Limited’s upcoming earnings report date is Mar 04, 2025 which is in 165 days.
How were Neuren Pharmaceuticals Limited’s earnings last quarter?
Neuren Pharmaceuticals Limited released its earnings results on Aug 27, 2024. The company reported AU$0.061 earnings per share for the quarter, missing the consensus estimate of AU$0.11 by -AU$0.049.
Is Neuren Pharmaceuticals Limited overvalued?
According to Wall Street analysts Neuren Pharmaceuticals Limited’s price is currently Undervalued.
Does Neuren Pharmaceuticals Limited pay dividends?
Neuren Pharmaceuticals Limited does not currently pay dividends.
What is Neuren Pharmaceuticals Limited’s EPS estimate?
Neuren Pharmaceuticals Limited’s EPS estimate is AU$0.58.
How many shares outstanding does Neuren Pharmaceuticals Limited have?
Neuren Pharmaceuticals Limited has 130,065,670 shares outstanding.
What happened to Neuren Pharmaceuticals Limited’s price movement after its last earnings report?
Neuren Pharmaceuticals Limited reported an EPS of AU$0.061 in its last earnings report, missing expectations of AU$0.11. Following the earnings report the stock price went down -2.603%.
Which hedge fund is a major shareholder of Neuren Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:NEU
---
Neuren Pharmaceuticals Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$26.50 (79.91% Upside)
AU$26.50 (79.91% Upside)
Blogger Sentiment
Bullish
AU:NEU Sentiment 96%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $67.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
33.13%
12-Months-Change
Fundamentals
Return on Equity
73.89%
Trailing 12-Months
Asset Growth
134.72%
Trailing 12-Months
Company Description
Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome.
---
NEU Company Deck
---
NEU Earnings Call
Q4 2024
0:00 / 0:00
---
NEU Stock 12 Month Forecast
Average Price Target
AU$26.50
▲(79.91% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Anavex Life Sciences
―
Cytokinetics
―
SAGE Therapeutics
―
Neuren Pharmaceuticals Limited
―
Best Analysts Covering NEU
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+22.24%
reiterated a buy rating last month
Copying Melissa Benson's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +22.24% per trade.
---